Blue Earth

Blue Earth Diagnostics Ltd Collaborates with Sinotau Pharmaceutical Group to Bring Prostate Cancer PET Diagnostic Imaging Agent, Flotufolastat (18F) Injection, to China

Retrieved on: 
Tuesday, October 17, 2023
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Diagnosis, Incidence, Partnership, 18F, Radiation, PET, Recurrence, Radiopharmaceutical, PSMA, Cancer, Janet Woodcock, Chinese, Prostate cancer, Blue Earth, CSCO, Patient, Medical imaging

It marks an important stage in the Blue Earth Diagnostics’ strategy to make flotufolastat (18F) available to patients and clinicians globally.

Key Points: 
  • It marks an important stage in the Blue Earth Diagnostics’ strategy to make flotufolastat (18F) available to patients and clinicians globally.
  • Yanmin Tang, CEO of Sinotau Pharmaceutical Group, said, “Sinotau Pharmaceutical Group is dedicated to the field of new generation radiopharmaceuticals.
  • We are pleased to form this strategic cooperation with Blue Earth Diagnostics and we look forward to making flotufolastat (18F) available to the clinical community in China.
  • It is engineered to advance clinical decision-making by providing useful information to guide treatment planning in men with prostate cancer.

Blue Earth Resources, Inc. Acquires Fuel Trader Supply and Fuel Trader Resource Management

Retrieved on: 
Monday, September 19, 2022
Benchmark, FTS, Blue Earth, RJ, Gasoline, Director, National Futures Association, Risk, LLC, U.S. Securities and Exchange Commission, Nature, Company, Acquisition, Smart contract, Commodity Futures Trading Commission, Forward-looking statement, Commonwealth, LLP, Colonial, Risk management, Terminology, Board, GLOBE, EF Hutton, Commodity broker, Plantation, Airline, Management, Retail

Scott M. Boruff, Chief Executive Officer, stated, Fuel Trader has long been a trusted strategic partner of ours.

Key Points: 
  • Scott M. Boruff, Chief Executive Officer, stated, Fuel Trader has long been a trusted strategic partner of ours.
  • FTRM offers full-service bulk fuel inventory management solutions, to include consulting services for the sourcing, logistics, and risk management needs of clients in the petroleum industry.
  • Blue Earth Resources, Inc. (OTCMKTS: BERI) procures refined fuels from refineries and wholesalers and distributes it to both large retailers and single site operators.
  • Due to such risks and uncertainties, actual events may differ materially from those reflected or contemplated in such forward-looking statements.

Blue Earth Resources Launches BluePetro Branded Fuel Offering for Southeast U.S. Convenience Stores

Retrieved on: 
Thursday, March 10, 2022
Industry, Small business, Biofuel, Company, Kerosene, LED, Risk management, Nature, POS, GLOBE, Sale, Gasoline, ARR, Blue Earth, Terminology, Forward-looking statement, Ethanol, Online shopping

Knoxville, TN, March 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Blue Earth Resources Inc. (OTCMKTS: BERI) ("Blue Earth" or the "Company"), a U.S. fuel marketer, announces the launch of BluePetro, a fuel brand serving southeast U.S. independent convenience store operators. 

Key Points: 
  • Knoxville, TN, March 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Blue Earth Resources Inc. (OTCMKTS: BERI ) ("Blue Earth" or the "Company"), a U.S. fuel marketer, announces the launch of BluePetro , a fuel brand serving southeast U.S. independent convenience store operators.
  • BluePetro is an extension of Blue Earth Resources and signifies calm confidence in delivery of best fuel value for southeast consumers.
  • Features for the operators include a complete branding package - LED price sign, canopy wrap, pump decals, paint refresh, safe and secure point of sale (POS) processing, and 10-year fuel supply contract through Blue Earth Resources.
  • Blue Earth Resources, Inc. is a fuel marketer which provides custom-designed solutions to refined fuel procurement supply issues and logistics challenges faced by fuel customers in the United States.

BRACCO IMAGING LAUNCHES NEW SUBSIDIARY, BLUE EARTH THERAPEUTICS, TO ADVANCE DEVELOPMENT OF NEXT GENERATION THERAPEUTIC RADIOPHARMACEUTICAL TECHNOLOGY

Retrieved on: 
Tuesday, March 1, 2022
Prostate cancer, Health, HIV disease progression rates, PET, Board, PSMA, Radiation, Magnetic resonance imaging, Man, Therapy, MRI, Bone marrow, Kidney, Acquisition, Precision medicine, Google Images, Molecular imaging, Biotechnology, Blue Earth, CEUS, Nuclear medicine, Cancer, Patient, Solution, CEO, 3D ultrasound, Medical imaging, Leonardo S.p.A.

Blue Earth Therapeutics has exclusive worldwide rights to therapeutic applications of radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) radiopharmaceutical technology.

Key Points: 
  • Blue Earth Therapeutics has exclusive worldwide rights to therapeutic applications of radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) radiopharmaceutical technology.
  • "We are increasingly committed to precision medicine," says Fulvio Renoldi Bracco, Vice-Chairman of the Board & CEO of Bracco Imaging S.p.A., the world leader in diagnostic imaging.
  • The creation of Blue Earth Therapeutics marks an exciting new direction for us in addressing important unmet needs in patient health."
  • Bracco Imaging S.p.A. ("Bracco Imaging"), part of the Bracco Group, is an innovative world leader delivering end-to-end products and solutions through its comprehensive portfolio across diagnostic imaging modalities.

BRACCO IMAGING LAUNCHES NEW SUBSIDIARY, BLUE EARTH THERAPEUTICS, TO ADVANCE DEVELOPMENT OF NEXT GENERATION THERAPEUTIC RADIOPHARMACEUTICAL TECHNOLOGY

Retrieved on: 
Tuesday, March 1, 2022
Prostate cancer, Health, HIV disease progression rates, PET, Board, PSMA, Radiation, Magnetic resonance imaging, Man, MILAN, Therapy, MRI, Bone marrow, Kidney, Acquisition, Precision medicine, Google Images, Molecular imaging, Biotechnology, Blue Earth, CEUS, Nuclear medicine, Cancer, Patient, Solution, CEO, 3D ultrasound, Medical imaging, Leonardo S.p.A.

MILAN, March 1, 2022 /PRNewswire/ -- Innovative rhPSMA Theranostic technology has the potential to offer both diagnostic imaging and treatment for patients affected by prostate cancer. Blue Earth Therapeutics has exclusive worldwide rights to therapeutic applications of radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) radiopharmaceutical technology.

Key Points: 
  • Blue Earth Therapeutics has exclusive worldwide rights to therapeutic applications of radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) radiopharmaceutical technology.
  • "We are increasingly committed to precision medicine," says Fulvio Renoldi Bracco, Vice-Chairman of the Board & CEO of Bracco Imaging S.p.A., the world leader in diagnostic imaging.
  • Bracco Imaging S.p.A. ("Bracco Imaging"), part of the Bracco Group, is an innovative world leader delivering end-to-end products and solutions through its comprehensive portfolio across diagnostic imaging modalities.
  • Bracco Imaging portfolio includes products and solutions for all key diagnostic imaging modalities: X-ray imaging, magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine.